Biomarker-Driven Targeted Therapies for Gastric/GEJ Malignancies

Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer-related mortality worldwide and is highly prevalent in East Asia, Middle and East Europe, and South America [2]. [Figure 1] Although Western countries have had a recent decline in the incidence of distal gastric adenocarcinomas, this has been accompanied by rising incidence of gastric cancers involving the gastric/GEJ junction (GEJ, gastro-esophageal junction), with the number of newly diagnosed cases increasing the most rapidly among US men between the ages of 25 to 39 years old [3].
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research